Zhejiang Sunflower Light Energy (SHE:300111) — Market Cap & Net Worth
Market Cap & Net Worth: Zhejiang Sunflower Light Energy (300111)
Zhejiang Sunflower Light Energy (SHE:300111) has a market capitalization of $565.08 Million (CN¥3.86 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #11725 globally and #3353 in its home market, demonstrating a -2.28% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Sunflower Light Energy's stock price CN¥3.00 by its total outstanding shares 1287210714 (1.29 Billion). Also see 300111 current and non-current assets for a full breakdown of the balance sheet.
Zhejiang Sunflower Light Energy Market Cap History: 2015 to 2026
Zhejiang Sunflower Light Energy's market capitalization history from 2015 to 2026. Data shows change from $1.24 Billion to $565.08 Million (-6.21% CAGR). Also see Zhejiang Sunflower Light Energy (300111) cash conversion ratio for how efficiently the company converts equity into cash flow.
Zhejiang Sunflower Light Energy Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Sunflower Light Energy's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Zhejiang Sunflower Light Energy (300111) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
4.25x
Zhejiang Sunflower Light Energy's market cap is 4.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $992.65 Million | $1.60 Billion | $30.64 Million | 0.62x | 32.39x |
| 2017 | $676.21 Million | $1.53 Billion | $23.70 Million | 0.44x | 28.53x |
| 2018 | $378.60 Million | $900.22 Million | -$1.12 Billion | 0.42x | N/A |
| 2019 | $440.76 Million | $836.61 Million | -$114.93 Million | 0.53x | N/A |
| 2020 | $602.75 Million | $286.96 Million | $55.87 Million | 2.10x | 10.79x |
| 2021 | $593.33 Million | $297.29 Million | $53.42 Million | 2.00x | 11.11x |
| 2022 | $614.05 Million | $335.86 Million | -$1.14 Million | 1.83x | N/A |
| 2023 | $572.61 Million | $338.42 Million | $21.75 Million | 1.69x | 26.33x |
| 2024 | $610.28 Million | $330.37 Million | $7.83 Million | 1.85x | 77.97x |
| 2025 | $1.15 Billion | $271.53 Million | -$4.38 Million | 4.25x | N/A |
Competitor Companies of 300111 by Market Capitalization
Companies near Zhejiang Sunflower Light Energy in the global market cap rankings as of September 19, 2026. Review Zhejiang Sunflower Light Energy tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Zhejiang Sunflower Light Energy by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Zhejiang Sunflower Light Energy Historical Marketcap From 2015 to 2026
Between 2015 and today, Zhejiang Sunflower Light Energy's market cap moved from $1.24 Billion to $ 565.08 Million, with a yearly change of -6.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥565.08 Million | -51.06% |
| 2025 | CN¥1.15 Billion | +89.20% |
| 2024 | CN¥610.28 Million | +6.58% |
| 2023 | CN¥572.61 Million | -6.75% |
| 2022 | CN¥614.05 Million | +3.49% |
| 2021 | CN¥593.33 Million | -1.56% |
| 2020 | CN¥602.75 Million | +36.75% |
| 2019 | CN¥440.76 Million | +16.42% |
| 2018 | CN¥378.60 Million | -44.01% |
| 2017 | CN¥676.21 Million | -31.88% |
| 2016 | CN¥992.65 Million | -19.91% |
| 2015 | CN¥1.24 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Zhejiang Sunflower Light Energy was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $565.08 Million USD |
| MoneyControl | $565.08 Million USD |
| MarketWatch | $565.08 Million USD |
| marketcap.company | $565.08 Million USD |
| Reuters | $565.08 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Sunflower Light Energy
Zhejiang Sunflower Great Health Co., Ltd. engages in the research, development, production, and sale of anti-infectious, cardiovascular, digestive system and other drugs in China and internationally. It offers clarithromycin API and tablets, anti-infective drugs used for nasopharyngeal infection, lower respiratory tract infection, skin and soft tissue infection, acute otitis media, Mycoplasma pne… Read more